OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
March 03, 2021
AstraZeneca has announced that the mass rollout of its COVID-19 vaccine has begun via the COVAX initiative.
March 02, 2021
Under the terms of the acquisition, OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies, WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit.
March 01, 2021
The companies intend to design and implement algorithms for the early stages of research for drug discovery and development of drug candidates to treat Alzheimer’s disease.
The new ultra-sensitive second-generation micro-chip technology is a key enabler in advanced single-cell proteomics workflow.
Through the acquisition, Merck will have access to Pandion’s pipeline of precision immune modulators targeting critical immune control nodes, including its lead candidate, PT101.
Through the partnership, Seven Bridges will centralize and manage terabytes of raw and processed scRNASeq data using its cloud-based bioinformatic analysis platform while working to expand Pfizer’s cloud platforms and capabilities.
February 25, 2021
The site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization.
The company will join the network of approved manufacturers of the lipid excipients.
Under the terms of the partnership, ICQ Consultants will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa's bioreactor systems and related products in the US.
February 24, 2021
Through the acquisition, PharmaLex will expand its capabilities in the biopharma sector while enhancing its global market reach with a new location in Australia.
The expansion, to be completed in April 2021 aims to increase the CDMO’s viral-vector production capacity in Spain.
February 23, 2021
The new facility is part of Bristol Myers Squibb’s investment into the clinical and commercial manufacturing of cell therapies for patients with aggressive hematological cancers.
Through the acquisition, Catalent will establish pDNA development and manufacturing services at its Rockville, MD, facility and will gain Delphi’s team of R&D and genetic engineering scientists, technicians, and regulatory specialists.
February 22, 2021
With the acquisition, Eurofins gets Beacon’s G-protein coupled receptor research knowledge and its compound library.
Once the vaccine has been authorized, Sanofi will provide Johnson & Johnson with access to its vaccine manufacturing plant in Marcy l’Etoile, France, to formulate and fill vials of the vaccine, at a rate of 12 million doses per month.
The second phase of the Myford facility expansion in California will add upstream and downstream processing suites.
February 18, 2021
The company has completed the expansion of its laboratory facilities to accommodate the development of APIs.
The companies have expanded their agreement to include the research and development of new therapies for influenza and other respiratory viruses.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.